BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17546767)

  • 1. [Results of enzyme replacement therapy in Fabry disease nephropathy].
    Dussol B
    Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
    Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
    J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy.
    Desnick RJ; Wasserstein MP; Banikazemi M
    Contrib Nephrol; 2001; (136):174-92. PubMed ID: 11688379
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal complications of Fabry disease.
    Basic-Jukic N; Kes P; Coric M; Basic-Kes V
    Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.
    Warnock DG; Thomas CP; Vujkovac B; Campbell RC; Charrow J; Laney DA; Jackson LL; Wilcox WR; Wanner C
    J Med Genet; 2015 Dec; 52(12):860-6. PubMed ID: 26490103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy.
    Torra R; Algaba F; Ars E; Santin S; Fernández-Llama P; Ballarin J
    Clin Nephrol; 2008 Jun; 69(6):445-9. PubMed ID: 18538121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease in children: agalsidase-beta enzyme replacement therapy.
    Borgwardt L; Feldt-Rasmussen U; Rasmussen AK; Ballegaard M; Meldgaard Lund A
    Clin Genet; 2013 May; 83(5):432-8. PubMed ID: 22880956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
    Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
    Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.
    Ito S; Ogura M; Kamei K; Matsuoka K; Warnock DG
    Pediatr Nephrol; 2016 Aug; 31(8):1369-73. PubMed ID: 27129690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
    Senocak Tasci E; Bicik Z
    Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of kidney involvement in Fabry disease.
    Warnock DG; West ML
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
    Mignani R; Cagnoli L
    J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.